Sie suchten nach: need for rescure inhaler (Dänisch - Holländisch)

need for post - marketing data
need for post- marketing data

description and grounds need for community intervention 22 objectives pursued
description and grounds need for community intervention 22 objectives pursued

på electronic arts' hjemmeside kan du læse mere om need for speed™: undercover.
ga naar electronic arts voor meer informatie over need for speed™: undercover.

they will be able to provide you with all the information you need for your removal and assist you with the relevant administrative procedures .
they will be able to provide you with all the information you need for your removal and assist you with the relevant administrative procedures .

concept paper on the development of a cpmp points to consider on the need for reproduction toxicity studies in the development of human insulin analogues
reproduction toxicity studies in the development of human insulin analogues

on the need for clarity in monetary policy-making » af b. winkler , august 2000 .
on the need for clarity in monetary policy-making » door b. winkler , augustus 2000 .

there is also an urgent need for a detailed study of the statistical systems put in place in member states and candidate countries in order to assess to what extent they are properly suited to providing good quality data .
there is also an urgent need for a detailed study of the statistical systems put in place in member states and candidate countries in order to assess to what extent they are properly suited to providing good quality data .

need for post- marketing data contribution to cpmp points to consider document on xenogeneic cell therapy proposals for revision to standard operating procedure on urgent safety restrictions for medicinal products authorised through the mutual recognition procedure
need for post-marketing data contribution to cpmp points to consider document on xenogeneic cell therapy proposals for revision to standard operating procedure on urgent safety restrictions for medicinal products authorised through the mutual recognition procedure

joint phvwp/ ewp concept paper on the development of a cpmp note for guidance on the use of medicinal products during pregnancy: need for post- marketing data
joint phvwp/ewp concept paper on the development of a cpmp note for guidance on the use of medicinal products during pregnancy: need for post-marketing data

63) note for guidance on photosafety testing points to consider document on the need for assessment of reproductive toxicity of human insulin analogues discussion paper on environmental risk assessments of non- gmo containing medicinal products for human use non- clinical documentation of medicinal products with ‘ well- established use ’ note for guidance on the need for non- clinical testing of pharmaceuticals in juvenile animals discussion paper on the non- clinical safety studies to support single low dose clinical screening studies in man note for guidance on specification limits for residues for heavy metal catalysts in medicinal products points to consider on xenogeneic cell therapy note for guidance on comparability of biotechnology products pre- clinical and clinical issues points to consider on the assessment of the potential for qt interval prolongation by non- cardiovascular medicinal products note for guidance on risk assessment of medicinal products on human reproductive and development toxicities: from data to labelling
63) note for guidance on photosafety testing; points to consider document on the need for assessment of reproductive toxicity in the development of human insulin analogues discussion paper on environmental risk assessments of non-gmo containing medicinal products for human use non-clinical documentation of medicinal products with ‘ well-established use’ note for guidance on the need for non-clinical testing of pharmaceuticals in juvenile animals discussion paper on the non-clinical safety studies to support single low dose clinical screening studies in man note for guidance on specification limits for residues for heavy metal catalysts in medicinal products points to consider on xenogeneic cell therapy note for guidance on comparability of biotechnology products pre-clinical and clinical issues points to consider on the assessment of the potential for qt interval prolongation by non-cardiovascular medicinal products note for guidance on risk assessment of medicinal products on human reproductive and development toxicities: from data to labelling